Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Actinium PharmaceuticalsATNM -0.89%17 Cash Ratio is 3.94 as of Jun. 2026, which is 53% below its 10-year median of 8.33. GuruFocus rates ATNM with a GF Score™ of 17/100. The stock has 4 warning signs investors should review. Among 1,355 Biotechnology companies, Actinium Pharmaceuticals ranks better than 56.83% on this metric.
Actinium Pharmaceuticals has a Cash Ratio of 3.94. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Actinium Pharmaceuticals's Cash Ratio or its related term are showing as below:
ATNM'
s Cash Ratio Range Over the Past 10 Years
Min: 1.26 Med: 8.33 Max: 21.15
Current: 3.94
During the past 13 years, Actinium Pharmaceuticals's highest Cash Ratio was 21.15. The lowest was 1.26. And the median was 8.33.
ATNM's Cash Ratio is ranked better than 56.83% of 1355
companies
in the Biotechnology industry
Industry Median: 2.96
vs ATNM: 3.94
Actinium Pharmaceuticals (AMEX:ATNM) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Actinium Pharmaceuticals Cash Ratio Related Terms
Actinium Pharmaceuticals Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Actinium Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Actinium Pharmaceuticals Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Actinium Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Actinium Pharmaceuticals (ATNM) has a Cash Ratio of 3.94 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Actinium Pharmaceuticals and its competitors. This is 53% below median its historical median of 8.33. Over the past decade, Actinium Pharmaceuticals' Cash Ratio has ranged from 1.26 to 21.15. According to the industry distribution chart, Actinium Pharmaceuticals ranks #585 out of 1355 companies in the Biotechnology industry, placing it in the top 43.2%.
Is Actinium Pharmaceuticals' Cash Ratio too high?
Actinium Pharmaceuticals' current Cash Ratio of 3.94 is 53% below median its 10-year median of 8.33. Over the past 10 years, this metric has ranged from a low of 1.26 to a high of 21.15. The Biotechnology industry median Cash Ratio is 2.96. Actinium Pharmaceuticals' value of 3.94 is 33.1% above this industry median. Based on the distribution chart, Actinium Pharmaceuticals ranks #585 out of 1355 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Actinium Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Actinium Pharmaceuticals' Cash Ratio compare to PSTV and IGC?
According to the Biotechnology industry distribution chart, Actinium Pharmaceuticals ranks #585 out of 1355 companies for Cash Ratio. This puts Actinium Pharmaceuticals in the upper half of its industry. The industry median Cash Ratio is 2.96. Actinium Pharmaceuticals' value of 3.94 is 33.1% above this benchmark. Historically, Actinium Pharmaceuticals' own Cash Ratio has ranged from 1.26 to 21.15 over the past decade. While the company's 10-year median is 8.33 vs. the industry median of 2.96, Actinium Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,355 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Actinium Pharmaceuticals's current Cash Ratio of 3.94 is 33.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Actinium Pharmaceuticals and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actinium Pharmaceuticals's current Cash Ratio is 3.94, which is 53% below median its own 10-year median of 8.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actinium Pharmaceuticals stock overvalued right now?
Actinium Pharmaceuticals (ATNM) has a current Cash Ratio of 3.94. The current Cash Ratio is 3.94, which is 53% below median its 10-year median of 8.33 and 33.1% above the Biotechnology industry median of 2.96. Actinium Pharmaceuticals' overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Actinium Pharmaceuticals (ATNM), the current Cash Ratio is 3.94 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
17GF Score
Get the complete analysis for ATNM
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATNM has been successfully added to your 
